We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral IMO-2125, we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.
Along with our research alliance partner, MD Anderson Cancer Center, we have recently completed enrollment in the dose escalation phase of our clinical trial of IMO-2125 in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients. Based on all of the evidence generated in the Phase 1 portion of the trial, we’ve selected the 8 mg dosage of IMO-2125 and have advanced to the Phase 2 portion of the trial which will enroll 21 patients at multiple clinical trial sites. We also are enrolling an arm in the trial to test the combination of IMO-2125 with Pemrolizumab and have recently initiated a multi-center clinical trial of IMO-2125 as a monotherapy in melanoma and numerous other solid tumors and plan to open additional trials to explore further combination regimens in other solid tumor types. For more information on these studies, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at firstname.lastname@example.org or visit Idera’s Clinical Trials Website.